$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Here, we present a technology platform and a technique which uses magnetic levitation coupled with automated imaging and analysis to analyze the density distribution of a patient's cells as an indicator for disease. This versatile approach for density-based cytometric analysis can ultimately be applied to a range of disease diagnostics. However, in order to be compatible with point-of-care testing and use in developing countries, the technique must satisfy requirements for low cost, portability, and usability. The device and consumables must be easily obtained at a low cost. The sample preparation must be simple, analysis should be automated with minimal requirements for user input or interpretation, and results should be returned quickly. Further, the device must be compact and portable to be useful in clinical settings as well as developing countries. Thus, we have developed a device and method to use magnetic levitation in point-of-care-compatible technology by coupling automated imaging and image analysis to return results regarding the density distribution of a population of a patient's cells.
Point-of-care technologies offer a notable advantage over current clinical laboratory testing procedures. The technology currently available is too expensive to be owned by a clinician or too complex to be carried out by medical staff. Many of these procedures require labor-intensive protocols which must be carried out by a trained technician. For these reasons, patient samples such as blood or urine are generally collected in the physician's office then transferred to a remote, centralized testing laboratory for clinical testing, which may take several days for the physician to receive the results of the test. This can cause delays or complications in the course of treatment in some cases, makes this testing very costly and inefficient (causing a financial burden on insurance payers), and further makes many diagnostics inaccessible in low-resource settings and developing countries.
Here, we present a magnetic levitation technique coupled with automated imaging and analysis in both a device with embedded imaging and processing (Figure 1) and a smartphone-compatible device (Figure 2). These magnetic levitation-based devices represent a broadly applicable platform technology which has the potential to be applied to a range of different medical diagnostic applications. The magnetic levitation approach functions based on an equilibrium between two forces: a magnetic force and a buoyancy force1,2,3. When a particle is suspended in a paramagnetic medium and inserted into a magnetic field generated by two magnets with like poles facing each other, a magnetic force acts on the particle in the direction toward the centerline between the two magnets. The buoyancy force is caused by the relative density of the particle compared to the suspending medium and is upward in the case of particles less dense than the medium and downward in the case of particles denser than the surrounding medium. Based on these two forces, particles will reach an equilibrium levitation position in the field which balances these two forces; this position is directly related to the density of the particle, with denser particles levitating lower in the field than less dense particles. An imaging module, either a built-in smartphone camera4,5,6 or independent optical components equipped with a magnifying lens7,8, are used to visualize the positions of the particles. Image processing, either through a smartphone application4,5,6 or an embedded processing unit7,8, then processes the captured images to quantify the spatial distribution and, therefore, the density distribution of the population. In order to analyze larger samples (such as those with only a few particles of interest per milliliter, flow can be integrated directly into the device such the particles are levitated and analyzed as they pass through the imaging region (Figure 2).

Figure 1: Self-contained Magnetic Levitation Platform. (a) Compact magnetic levitation device including a magnetic focusing module, imaging components (a light-emitting diode (LED), an optical lens, and a camera detector), and a processing unit with a display screen. (b) Magnetic field strength in the cross-section of the area between the magnets where the sample is inserted. The field strength is greatest at the surface of the magnets and approaches zero at the centerline between them. (c) Particles, such as cells, within the magnetic field experience several forces: a magnetic force (Fm) toward the centerline between the magnetics, with magnitude varying based on the position of the particle; a gravitational force (Fg') which depends on the particle density relative to that of the suspending medium, and a drag force (Fd) resisting the particle motion. Reproduced, with permission, from Yenilmez, et al.8 Please click here to view a larger version of this figure.

Figure 2: Smartphone-compatible Flow-assisted Magnetic Levitation Platform. (a-c) Front (a), side (b), and back (c) views of magnetic levitation device (d) The components of the device include: 1) Magnetic levitation module, including permanent magnets, a magnifying lens, and an LED and light diffuser, 2) smartphone case, 3) electronics, including a microcontroller, pump driver, and Bluetooth receiver, 4) micro-pump holder, 5) adjustable orifice, 6) waste tube holder, 7) battery holder, 8) sample holder, 9) dual-purpose stand and cover. (e) Flow schematic, showing pumping of the sample through the magnetic field. (f) Cross-section of the magnetic levitation module, showing how particles of different densities will align as they are pumped through the field; less dense particles, such as Particle 1, will equilibrate at a higher levitation height than denser particles, such as Particle 2. Reproduced, with permission, from Amin, et al.1 Please click here to view a larger version of this figure.
The minimum requirements for use of any sample for density distribution analysis in this system include the ability to obtain a suspension of cells or particles greater than approximately 5 µm and less than approximately 250 µm in size (for imaging and image processing) and its compatibility with mixing in a solution of a paramagnetic solution such as the gadobutrol used here. For disease diagnostics, compatible applications include those in which (i) cells of interest inherently have an altered density when they carry a disease compared to healthy controls, (ii) a density change can be induced in the cell by addition of a reagent or some alternative treatment for a short incubation time, or (iii) different cell types are being identified in a single sample and inherently (or via some treatment) have unique characteristic densities.
Sickle cell disease is a genetic disorder causing a mutated form of hemoglobin, HbS, to be produced in a person's red blood cells (RBCs), which can result in intermittent vaso-occlusive events and chronic hemolytic anemia9. It is diagnosed using either hemoglobin isoelectric focusing, high-performance liquid chromatography (HPLC) fractionation, or hemoglobin electrophoresis which are highly accurate but must be performed in a clinical testing laboratory because they are incompatible with point-of-care settings. Solubility and paper-based tests for sickle cell disease have been proposed, but generally require subjective user interpretation and confirmatory testing. Here, we use a density-based approach to identify sickle RBCs, which attain a higher density than RBCs from people without sickle cell disease. The mechanism involves polymerization of the mutated form of hemoglobin, HbS, which causes RBC dehydration in sickle cell disease RBCs under deoxygenated conditions10,11,12,13.
This density-based approach can also be applied to separate cells of different types on the basis of density: white blood cells (WBCs) and RBCs7. WBCs are generally responsible for fighting infections in the body. WBC cytometry can be used to quantify the number of these cells in the blood and serves as a useful diagnostic tool. WBC counts higher than normal (generally considered greater than 11,000 cells per µL) may indicate infection, immune system disorders, or leukemia. WBC counts below the normal range (around 3,500 cells per µL) may be caused by autoimmune disorders or conditions which damage bone marrow. Unlike alternative technologies, the process presented here does not rely on lysis of the RBCs or stains in order to identify WBCs. This cell-based test takes advantage of the unique inherent densities of the two cell types to perform separation, as the WBC population density has been reported to be lower than that of the RBC population as calculated previously using density gradient centrifugation1,5,8.
Compared to alterative testing at remote locations, this test is rapid, with simple sample preparation (Figure 3), separation of cells in the device within 10 - 15 min, and automated imaging and analysis which requires less than 1 min. In this way, the device can return results quickly to better inform medical decisions, allow treatment to be administered immediately to alleviate physical and psychological pain, and reduce the risk of complications associated with a delay in medical care. This technique can be performed on-site either in clinical settings due to simple sample preparation and automated imaging and analysis which returns a result with minimal user input or interpretation. Because of the use of a simple approach using permanent magnets for sample analysis and the use of either a smartphone or simple electrical components for imaging and image processing, the device as well as the per-test costs are minimal compared to some sophisticated testing procedures.